Next Phase Newsletter

A corporate venture arm of a diversified business based in Japan is focused on three primary sectors, one of them being healthcare. The team has offices throughout the USA.  The fund has an evergreen structure looking to allocate between $1-$3 million per deal initially and up to $5 million over the life of the investment. They are seeking to invest in approximately 2-4 companies over the next 12 months and are open to investing in companies across the globe.

Sectors of interest include: pharmaceuticals, medical device and digital health. Therapeutic and product areas of interest include: Pain, critical care, musculoskeletal disease, kidney disease, DDS, patient monitoring technologies, bioprocessing technologies, digital therapeutics. The firm is open to all stages of investment, with a general preference toward companies with at least some early clinical data.

The firm invests in private companies and is willing to work with all types of management teams including incomplete teams. The firm generally requests at least an observer seat following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture builder headquartered in Western Europe seeks to build new ventures from scratch, generating innovation in novel science and technology from the earliest stages of development. Currently, the firm is focused on 4 main pillars: energy, agriculture, curative therapeutics, and computation. The firm invests pre-seed/seed capital into the companies they build. The firm will consider global opportunities.

Within life sciences, the firm is indication agnostic and has worked in areas including cystic fibrosis, oncology, neurodegeneration and microbiome. The firm has a strong interest in cell & gene therapy and synthetic biology, but is open to considering all other modalities – the firm has also launched companies that work on a more traditional approach.

In terms of stage of development, the firm invests in the companies it builds at formation stage and is open to working together with other organizations to undertake company creation and support proof-of-concept data generation. The firm generally does not currently build, or invest in, medical devices, diagnostics, or digital health companies.

As a venture builder, the firm does not have strict requirements or expectations on company operations or management team. The firm has generally built companies in Western Europe. That said, the firm has worked with scientists all across the globe to build its companies, and their portfolio also includes companies in other geographies such as the USA.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An evergreen strategic venture capital fund of big pharma closed at $100 million in 2013, and is managed by a small, dedicated team based in Massachusetts and California. The fund focuses on investments in companies developing pioneering bioelectronic medicines/ neuromodulation device and related enabling technologies. The initial investments are typically ranging from $5-$7 million in Series A, and the fund will also consider follow-on investments. The firm looks for investment opportunities globally.

The firm is dedicated to advancing bioelectronic medicines and is looking to invest in high-return opportunities in three areas: (1) Teams pursuing new therapies for existing peripheral neurostimulation devices. (2) Teams developing novel bioelectronic medicine technologies for existing neurostimulation therapies. (3) Companies introducing advanced technologies that are enabling for bioelectronics medicines. The firm is particularly interested in improved neural interfaces, novel power sources and wireless powering technology, ultra-low power chip architectures, sensors that can close-the-loop for adaptive therapies and new implantation and imaging methods. The firm is stage agnostic.

The firm typically will take board of directors or board observer seat, but it is not necessary. The fund exclusively invests in privately-held companies and primarily in pre-revenue companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

A venture capital firm was founded in 2013 with headquarters in Germany. The firm operates from 16 different offices across the globe and has invested in hundreds of companies in a wide variety of sectors. Recently, the firm has been expanding their portfolio in the life science/healthcare sector, and is actively seeking early-stage opportunities. Investing from a $1.5B fund, the firm will typically invest up to $3M as an initial check, with a significant portion of their capital dedicated to follow-on investments. The firm is open to global opportunities, with a focus on USA, Europe, and Asia.

The firm is interested in therapeutics, diagnostics, digital health, and life science tools. The firm’s interest areas also include industrial biotechnology, synthetic biology, and robotics. While the firm does not completely rule out medical device opportunities, they are not a priority for the firm. Within therapeutics, the firm will consider both single assets and platform technologies. In general, the firm is stage and indication agnostic.

The firm has no specific company or management team requirements and is open to working with all types of management teams. The firm can act as a lead, co-lead, or co-investor, and provides operational support for their portfolio companies to help them scale.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

A venture capital company was founded in 2005 and located in California. The firm manages just under $70 million in assets across 2 funds and makes equity investments into companies ranging from a few hundred thousand dollars to $2million with additional capital reserved for follow on rounds. The firm is looking for companies located throughout the United States and plans to make 4 new investments over the next 6-9 months.

The firm is looking for companies developing Medical Devices and Diagnostics, Healthcare IT products and Life Science Research Tools with an emphasis on fast to market low capital intense products that reduce the cost of delivering quality healthcare. For Healthcare IT investments the firm is most interested in machine learning and artificial intelligence (AI) applications and is generally not interested in Telehealth and EMR solutions. The firm is open to all sub-sectors and indications in the Medical technology space except for those targeting diseases and disorders of the spine. The firm will invest in both seed and later stage companies.

The firm is looking for companies with skilled and experienced management teams. The firm generally looks to take a board seat into companies after investment and play and active role in the management. The firm is willing to invest in both public and privately held companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The firm is a venture capital firm founded in 2012 and based in Missouri. The firm manages three healthcare and life sciences funds for a combined total of $60 million in assets under management. The firm’s first life science focused fund was launched in 2013 with $15 million of capital to invest. The firm looks to make equity investments of approximately $500k – $1 million into companies with additional capital reserved for follow on rounds. The firm looks to act as a bridge with its investments between the Seed and Series A round. The firm is also open to syndication with other investors for larger deals. The firm focuses its investments in the Midwest but is open to companies located throughout the US and makes approximately 6-8 investments per year.

The firm has recently launched a new healthcare fund in collaboration with another VC fund, resulting in the firm’s focus has shifted more Healthcare IT and Digital Health, with a specific focus on how healthcare delivery has changed during the COVID 19 pandemic. Examples of the subsectors of interest are: remote care, Healthcare IT for hospital efficiency, and response infrastructure systems. The firm is opportunistic in terms of indication.

The firm looks for management teams with domain experience, and is comfortable with working with incomplete or scientific founding teams. The firm prefers to take a board seat into companies following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The firm is a private investment firm based in New York. The firm is supported by a family who has invested in healthcare operating companies and real estate for over 30 years and seeks to invest in opportunities that align with their strategic interests. Investments in healthcare have included skilled nursing facilities, rehabilitation therapy, institutional pharmacy, hospice, mental health tech, healthcare tech, and home health. The firm looks to work with early stage companies where they can leverage their operating platform. As a private investor, the firm has a very flexible horizon and mandate – investment size can greatly vary on a deal-by-deal basis. The firm has about 20 companies in their its portfolio, and invests all across the USA.

The firm has a robust portfolio that ranges from healthcare to technology to consumer products. While the firm has a broad interest in healthcare, the firm is most interested in technologies that can leverage the firm’s operating platform and resources. The firm’s portfolio companies include workforce transformation, nurse staffing, medical billing, and Fintech that is focused on the healthcare sector, medical billing, and more. The firm also has a strong interest in technologies dedicated to mental & behavioral health. The firm is opportunistic in terms of stage of development. The firm does not consider therapeutics opportunities.

The firm seeks to partner with smart, thoughtful founders with a true commitment in their ideas. The firm is a hands-on investor and seeks to have an active role in their portfolio companies. As mentioned above, the firm is able to leverage its resources to support pilots and enable companies

to test new ideas. The firm can also support companies in enhancing their business models, implementing scale through partnerships, and share their own experiences in developing world-class brands.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.